Dr. Reddy's Laboratories
) recently announced the launch of its generic version of
Merck & Co
) blockbuster asthma and allergy drug Singulair (montelukast)
following the receipt of US Food & Drug Administration (FDA)
approval for its Abbreviated New Drug Application (ANDA).
Dr. Reddy's launched its generic version of Singulair tablets
(10 mg) and chewable tablets (4 mg & 5 mg) in the US on August
6, 2012. Singulair is marketed for the chronic treatment of asthma
symptoms and relieving symptoms of allergic rhinitis in both adults
According to IMS Health, US branded sales of Singulair tablets
and chewable tablets were approximately $3.6 billion and $1.14
billion, respectively, for the twelve months ended March 31,
Earlier this month, Singulair lost patent exclusivity in the US.
) also launched its generic version of Singulair tablets (10 mg)
and chewable tablets (4mg &5 mg) following FDA approval.
Dr. Reddy's had quite a few generic launches this year. In July
2012, it launched its generic version of
) blockbuster cholesterol drug, Lipitor. The FDA had approved the
company's ANDA for its generic version of Lipitor (10 mg, 20 mg, 40
mg and 80 mg formulations). Lipitor lost patent exclusivity in the
US on November 30, 2011.
Dr. Reddy's also launched a generic version of
) Boniva tablets for the treatment of osteoporosis in women after
menopause. A generic version of Boniva is also currently marketed
Watson Pharmaceuticals Inc.
We currently have a Neutral recommendation on Dr. Reddy's.
However, the stock carries a Zacks #1 Rank (short-term Strong Buy
rating). We believe that generic launches will continue to
drive revenues at Dr. Reddy's Global Generics segment, which
climbed 32% to $343 million in the second quarter of 2012.
Primary contribution came from both North America and Russia and
other CIS (Commonwealth of Independent States) markets (up 38%)
followed by India (up 19%) and Europe (up 14%). Growth was mainly
driven by new generic launches and an increase in the market share
of existing key products.
MERCK & CO INC (MRK): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
DOCTOR REDDYS (RDY): Free Stock Analysis Report
(RHHBY): ETF Research Reports
WATSON PHARMA (WPI): Free Stock Analysis Report
To read this article on Zacks.com click here.